Get started
Author

Anish Puliyayil

Observed name: A. Puliyayil
ORCID: 0000-0001-9825-6773
Observed ORCID: 0000-0001-9825-6773
OpenAlex ID: A5006965339
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
2024 · Lise J Estcourt, Zoe K McQuilten, et al. · The Lancet Haematology · 17
P946: a Phase I/ii Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Amarc 19-02 Belacard Study.
2022 · M. Lasica, A. Spencer, et al. · HemaSphere · 5
A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
2021 · David M Ross, Alejandro Arbelaez, et al. · Blood · 4
Intravascular large B-cell lymphoma: representative cases and approach to diagnosis
2021 · James Llewellyn Barker, Oshi Swarup, et al. · BMJ Case Reports · 4
A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study
2023 · Masa Lasica, Andrew Spencer, et al. · Blood · 3
Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
2021 · Slavisa Ninkovic, Nicholas E. Murphy, et al. · Blood · 1
PA-424 Risk-Directed Front-Line Therapy for Newly Diagnosed Multiple Myeloma (NDMM) incorporating selinexor - The RIDDLE-MX Trial AMaRC 21-04
2026 · Sueh-li A. Lim, Yu Jin Kim, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-838: Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
2026 · Rami Komrokji, Maria Diez Campelo, et al. · Clinical Lymphoma Myeloma & Leukemia
MDS-838: Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
2026 · Rami Komrokji, Maria Diez Campelo, et al. · Clinical Lymphoma Myeloma & Leukemia
Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial
2025 · Lynette Chee, Shuhying Tan, et al. · Blood
PDF
Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
2023 · Slavisa Ninkovic, Costas K. Yannakou, et al. · Blood
PDF
OAB-048: An interim analysis of a phase I/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMaRC 19-02 BelaCarD study
2022 · Masa Lasica, Andrew Spencer, et al. · Clinical Lymphoma Myeloma & Leukemia
P776: a Phase 2, Open-label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
2022 · S. Tan, A. Arbelaez, et al. · HemaSphere
A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia
2021 · Sung-Soo Yoon, Dong-Yeop Shin, et al. · Blood
Works count: 14
Citation count: 34
H-index: 4
I10-index: 1
Year
Topic
Type